Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.1.01 CHF
Change Today +0.03 / 3.06%
Volume 254.4K
CYTN On Other Exchanges
SIX Swiss Ex
As of 11:43 AM 04/30/15 All times are local (Market data is delayed by at least 15 minutes).

cytos biotechnology ag-reg (CYTN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/15 - SFr.2.60
52 Week Low
05/9/14 - SFr.0.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cytos biotechnology ag-reg (CYTN) Related Businessweek News

No Related Businessweek News Found

cytos biotechnology ag-reg (CYTN) Details

Cytos Biotechnology AG, a biopharmaceutical company, focuses on the discovery, development, and commercialization of biopharmaceutical products for use in the treatment and prevention of chronic diseases in Switzerland. The company’s lead product candidate is CYT003, which has completed Phase 2b clinical trials for the treatment of allergic asthma. It is developing CYT003 using Qb VLP platform, a vaccine platform based on bacteriophage Q beta-derived virus-like particles (Qb VLPs), which act as immune-stimulatory carriers for disease-associated antigens. The company has collaboration agreements with Novartis for the development of CAD106, an active immunotherapy for the treatment of patients with Alzheimer’s disease; Pfizer for developing a novel anti-IgE vaccine for Qb VLP platform; and Singapore’s Agency for Science, Technology and Research for the research, development, and commercialization of an influenza vaccine. Cytos Biotechnology AG is based in Schlieren, Switzerland.

cytos biotechnology ag-reg (CYTN) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: SFr.701.7K
Compensation as of Fiscal Year 2013.

cytos biotechnology ag-reg (CYTN) Key Developments

Novartis Buys Out CAD 106 License Agreement for CHF 4 Million from Cytos Biotechnology AG

Cytos Biotechnology Ltd. announced that Novartis has agreed to make a one-time payment of CHF 4 million to eliminate any further payment obligations under the Collaborative Research, Option and License Agreement for CAD 106, which is under development by Novartis for the prevention of Alzheimer's disease. Cytos is planning to use the payment from Novartis to settle remaining payment obligations under the outstanding convertible loan notes, which remain subordinated. The closing of the transaction with Novartis is expected to occur upon the conversion of the convertible bonds into Cytos shares in the second half of April 2015 and certain other closing conditions.

Cytos Biotechnology AG, Special/Extraordinary Shareholders Meeting, Mar 16, 2015

Cytos Biotechnology AG, Special/Extraordinary Shareholders Meeting, Mar 16, 2015., at 10:00 Central European Standard Time. Location: Cytos' offices. Agenda: To approve the share capital increase which is needed to create the shares for the conversion of the convertible bonds into equity.

Cytos Biotechnology AG Exclusively Licenses VLP Platform for the Treatment of Hepatitis B Infections to OnCore Biopharma

Cytos Biotechnology Ltd. announced that it executed an exclusive license agreement granting OnCore Biopharma Inc. access to Cytos' clinically validated virus like particle (VLP) platform for the use in the treatment and prevention of hepatitis B viral infections. Cytos also granted an option for the treatment of additional viral diseases other than influenza. The agreement will become effective with the achievement of certain closing conditions, including a successful debt restructuring of Cytos. For the first product in each of six possible product categories in the field of Hepatitis B that may be developed under the agreement, Cytos may receive up to USD 67 million in development milestones, or a maximum of USD 402 million if one product in each product category is developed. In addition, Cytos is eligible to receive commercial milestone payments of up to USD 120 million upon achievement of certain sales levels, and up to double-digit royalties on net sales from any successfully developed product.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTN:SW SFr.1.01 CHF +0.03

CYTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTN.
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOS BIOTECHNOLOGY AG-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at